Invesco Exchange-Traded Fund Trust II has released its latest financial report, highlighting its assets and liabilities as of August 31, 2026. This update is significant as it reflects the company's ongoing performance in the investment management sector, particularly amidst fluctuating market conditions.
Invesco Exchange-Traded Fund Trust II, classified as an investment entity, is based in Downers Grove, Illinois. The company operates under the SEC file number 811-21977 and has undergone name changes in the past, including its former identity as PowerShares Exchange-Traded Fund Trust II. The latest filing, submitted on October 30, 2026, indicates a total asset value of approximately $1.44 billion, with liabilities reported at around $36 million.
The NPORT-P filing reveals that the trust's net assets amount to approximately $1.41 billion. The report also highlights the performance of its key investment, the Invesco S&P Ultra Dividend Revenue ETF, which is a significant part of its portfolio. The filing states, "The total assets reported are $1,442,940,073.29, and total liabilities are $36,086,113.16." This data underscores Invesco's strong position in the investment management industry.
Invesco's financial update may impact various stakeholders, including investors, asset managers, and competitors in the investment management sector. The report showcases the trust's ability to navigate market challenges effectively, which may influence investor confidence and competitive strategies within the industry.
Looking ahead, the filing does not specify any immediate actions or future plans. However, the consistent reporting of financials suggests that Invesco is committed to transparency and maintaining its market presence. Investors and industry analysts will likely keep a close watch on the trust's performance in the upcoming quarters.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






